0001209191-23-057407.txt : 20231205
0001209191-23-057407.hdr.sgml : 20231205
20231205161854
ACCESSION NUMBER: 0001209191-23-057407
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231201
FILED AS OF DATE: 20231205
DATE AS OF CHANGE: 20231205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ticho Barry
CENTRAL INDEX KEY: 0001780088
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38938
FILM NUMBER: 231466825
MAIL ADDRESS:
STREET 1: C/O STOKE THERAPEUTICS, INC.
STREET 2: 45 WIGGINS AVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Stoke Therapeutics, Inc.
CENTRAL INDEX KEY: 0001623526
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471144582
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 781-430-8200
MAIL ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
FORMER COMPANY:
FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141028
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-01
0
0001623526
Stoke Therapeutics, Inc.
STOK
0001780088
Ticho Barry
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
BEDFORD
MA
01730
0
1
0
0
Chief Medical Officer
0
Employee Stock Option (Right to Buy)
20.25
2023-12-01
4
D
0
60000
D
2030-03-24
Common Stock
60000
0
D
Employee Stock Option (Right to Buy)
60.00
2023-12-01
4
D
0
65600
D
2031-03-01
Common Stock
65600
0
D
Employee Stock Option (Right to Buy)
20.34
2023-12-01
4
D
0
107400
D
2032-03-14
Common Stock
107400
0
D
Restricted Stock Unit (RSU)
2023-12-01
4
A
0
60773
0.00
A
2025-12-01
Common Stock
60773
60773
D
The canceled option vested as to 1/48th of the total award on April 25, 2020 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date.
On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 60,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 18,749 restricted stock units.
The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date.
On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,600 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,463 restricted stock units.
The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date.
On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 107,400 shares of Common Stock of the Issuer and in exchange issued to the reporting person 33,561 restricted stock units.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
48,792 restricted stock units will vest on December 1, 2024 and 11,981 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.
/s/ Stephen Tulipano, Attorney-in-Fact
2023-12-05